Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions
Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)
DOI: 10.1002/cpdd.70053 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 31.03.2026. Verfasst von Sudershan Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sun Pharmaceutical Industries Limited, Mumbai, India. Hauptthemen laut MEDLINE: Hydrocarbons, Fluorinated, Pyrimidines. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Pharma Laboratories.
Abstract (Originalsprache)
Elagolix is a short‐acting oral gonadotropin‐releasing hormone antagonist utilized for treating endometriosis‐associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use in Indian women remain limited. This study evaluated the pharmacokinetics, safety, and bioequivalence of a test 200 mg Elagolix tablet against a reference formulation under fasting conditions. The randomized, open‐label, four‐period crossover trial involved 60 healthy women aged 18‐40 years who received single oral doses of either formulation. Plasma concentrations were monitored via validated UHPLC‐MS/MS for 24 h post‐dose. Fifty‐nine participants completed the study, with results indicating rapid absorption (median T max 1.25‐1.50 h) and a mean half‐life of approximately 2.1‐2.2 h. Bioequivalence was established as the 90% confidence intervals for key pharmacokinetic parameters—C max , AUC 0‐t , and AUC 0‐∞ —fell within the regulatory 80%‐125% acceptance limits. Specifically, the median AUC 0‐t was 3341.23 ng h/mL for the test product compared to 3365.30 ng h/mL for the reference. Both formulations exhibited comparable safety profiles, with only five mild, resolvable adverse events reported. These findings confirm that the test formulation is bioequivalent to the reference standard, supporting its viability as a safe and effective therapeutic alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sun Pharmaceutical Industries Limited, Mumbai, India.
- Sun Pharma Laboratories Limited, Mumbai, India.
Förderung
- Sun Pharma Laboratories
Zitieren
APA
Kumar, S., Khuroo, A., Quadros, R., Dharmadhikari, S., Khandhedia, C., Puppalwar, G., & Mane, A. (2026). Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70053
Vancouver
Kumar S, Khuroo A, Quadros R, Dharmadhikari S, Khandhedia C, Puppalwar G, et al. Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70053
BibTeX
@article{Kumar2026,
author = {Kumar, Sudershan and Khuroo, Arshad and Quadros, Reshma and Dharmadhikari, Shruti and Khandhedia, Chintan and Puppalwar, Gaurav and Mane, Amey},
title = {Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cpdd.70053}
}
EUVIMED